EMEA Grants First Positive Opinion Under Accelerated Assessment To Soliris
This article was originally published in The Pink Sheet Daily
Executive SummaryAlexion’s treatment for a rare blood disease met CHMP’s criteria for accelerated review.
You may also be interested in...
NICE is undeniably impressed with Alexion’s Soliris for treating aHUS but wants more data to justify its eye-watering price tag.